全文获取类型
收费全文 | 2316篇 |
免费 | 191篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 70篇 |
妇产科学 | 101篇 |
基础医学 | 279篇 |
口腔科学 | 27篇 |
临床医学 | 188篇 |
内科学 | 668篇 |
皮肤病学 | 37篇 |
神经病学 | 146篇 |
特种医学 | 152篇 |
外科学 | 170篇 |
综合类 | 29篇 |
一般理论 | 3篇 |
预防医学 | 232篇 |
眼科学 | 21篇 |
药学 | 109篇 |
肿瘤学 | 282篇 |
出版年
2021年 | 30篇 |
2020年 | 15篇 |
2019年 | 34篇 |
2018年 | 37篇 |
2017年 | 23篇 |
2016年 | 29篇 |
2015年 | 34篇 |
2014年 | 51篇 |
2013年 | 59篇 |
2012年 | 115篇 |
2011年 | 134篇 |
2010年 | 57篇 |
2009年 | 49篇 |
2008年 | 124篇 |
2007年 | 128篇 |
2006年 | 99篇 |
2005年 | 89篇 |
2004年 | 91篇 |
2003年 | 85篇 |
2002年 | 74篇 |
2001年 | 71篇 |
2000年 | 64篇 |
1999年 | 61篇 |
1998年 | 37篇 |
1997年 | 30篇 |
1996年 | 19篇 |
1995年 | 17篇 |
1994年 | 19篇 |
1993年 | 17篇 |
1992年 | 57篇 |
1991年 | 56篇 |
1990年 | 54篇 |
1989年 | 52篇 |
1988年 | 46篇 |
1987年 | 57篇 |
1986年 | 55篇 |
1985年 | 44篇 |
1984年 | 46篇 |
1983年 | 35篇 |
1982年 | 22篇 |
1981年 | 15篇 |
1980年 | 16篇 |
1979年 | 22篇 |
1978年 | 15篇 |
1977年 | 18篇 |
1976年 | 17篇 |
1975年 | 11篇 |
1974年 | 27篇 |
1973年 | 21篇 |
1972年 | 13篇 |
排序方式: 共有2516条查询结果,搜索用时 15 毫秒
1.
2.
3.
Payal Shah Silvie Suriany Roberta Kato Adam M. Bush Patjanaporn Chalacheva Saranya Veluswamy Christopher C. Denton Kelly Russell Maha Khaleel Henry J. Forman Michael C. K. Khoo Richard Sposto Thomas D. Coates John C. Wood Jon Detterich 《American journal of hematology》2021,96(1):31-39
Sickle cell disease (SCD) is a monogenic hemoglobinopathy associated with significant morbidity and mortality. Cardiopulmonary, vascular and sudden death are the reasons for the majority of young adult mortality in SCD. To better understand the clinical importance of multi‐level vascular dysfunction, in 2009 we assessed cardiac function including tricuspid regurgitant jet velocity (TRV), tissue velocity in systole(S′) and diastole (E′), inflammatory, rheologic and hemolytic biomarkers as predictors of mortality in patients with SCD. With up to 9 years of follow up, we determined survival in 95 children, adolescents and adults with SCD. Thirty‐eight patients (40%) were less than 21 years old at initial evaluation. Survival and Cox proportional‐hazards analysis were performed. There was 19% mortality in our cohort, with median age at death of 35 years. In the pediatric subset, there was 11% mortality during the follow up period. The causes of death included cardiovascular and pulmonary complications in addition to other end‐organ failure. On Cox proportional‐hazards analysis, our model predicts that a 0.1 m/s increase in TRV increases risk of mortality 3%, 1 cm/s increase in S′ results in a 91% increase, and 1 cm/s decrease in E′ results in a 43% increase in mortality. While excluding cardiac parameters, higher plasma free hemoglobin was significantly associated with risk of mortality (p=.049). In conclusion, elevated TRV and altered markers of cardiac systolic and diastolic function predict mortality in a cohort of adolescents and young adult patients with SCD. These predictors should be considered when counseling cardiovascular risk and therapeutic optimization at transition to adult providers. 相似文献
4.
Ibrahim Aldoss Muhammad O. Kamal Stephen J. Forman Vinod Pullarkat 《Biology of blood and marrow transplantation》2019,25(2):e41-e45
Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a subset of high-risk B cell ALLs. A large proportion of Ph-like ALL cases carry activating kinase mutations that could potentially allow them to be targeted by tyrosine kinase inhibitors. Ph-like ALL is not an uncommon entity, especially among adults, with a frequency exceeding 20%, including in older patients (>60 years old) with ALL. Ph-like ALL is associated with inferior outcomes across all ages, and studies have consistently shown a higher incidence of persistent postinduction minimal residual disease in patients carrying Ph-like ALL compared with other subgroups of ALL, and this translates into inferior leukemia-related outcomes. The inferior outcome of conventional chemotherapy for Ph-like ALL in adults raises the fundamental question of whether all adults with Ph-like ALL require an allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) regardless of other presenting features and treatment response parameters. Here we present and discuss several scenarios in which adults with Ph-like ALL underwent or were considered for HCT in CR1 for various reasons. Although the decision to proceed with HCT was clear and indisputable in some of these situations, in others we struggled with the decision to transplant in CR1 because of the lack of published data regarding the efficacy of allogeneic HCT as consolidation for Ph-like ALL. We emphasize the urgent need for developing well-designed studies to address this important question. 相似文献
5.
Amandeep Salhotra Matthew Mei Tracey Stiller Sally Mokhtari Alex F. Herrera Robert Chen Leslie Popplewell Jasmine Zain Haris Ali Karamjeet Sandhu Elizabeth Budde Auayporn Nademanee Stephen J. Forman Ryotaro Nakamura 《Biology of blood and marrow transplantation》2019,25(2):287-292
The current standard of care for patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) is high-dose conditioning followed by autologous stem cell transplantation (ASCT). For some patients (ie, those with highest-risk disease, insufficient stem cell numbers after mobilization, or bone marrow involvement) allogeneic hematopoietic cell transplantation (alloHCT) offers the potential for cure. However, the majority of patients undergoing alloHCT receive reduced-intensity conditioning as a preparative regimen, and studies assessing outcomes of patients after alloHCT with myeloablative conditioning are limited. In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018. With a median follow-up of 2.6 years (range, 1.0 to 11.2 years), the probabilities of 2-year overall survival and event-free survival were 58.3% (95% confidence interval [CI], 35.0% to 75.8%) and 45.5% (95% CI, 24.4% to 64.3%), respectively. The cumulative incidence of grade II to IV acute GVHD was 45.5% (95% CI, 23.8% to 64.9%), with only 1 patient developing grade IV acute GVHD. However, chronic GVHD was seen in 55% of the patients (n?=?12). Of the 22 eligible patients, 2 had undergone previous ASCT and 2 had undergone previous alloHCT. Both patients with previous ASCT developed severe regimen-related toxicity. Patients who underwent alloHCT with chemorefractory disease had lower survival rates, with 1-year OS and EFS of 44.4% and 33.0%, respectively. In conclusion, alloHCT with a BEAM preparative regimen and tacrolimus/sirolimus-based GVHD should be considered as an alternative option for patients with highest-risk lymphoma whose outcomes are expectedly poor after ASCT. 相似文献
6.
Valerie L. Forman–Hoffman Kathryn R. Batts Sarra L. Hedden Kathy Spagnola Jonaki Bose 《Annals of epidemiology》2018,28(7):468-474
Purpose
To examine the prevalence and correlates of mental disorder comorbidity in the adult U.S. household population.Methods
Data are from a nationally representative sample of noninstitutionalized, civilian adults aged 18 years or older (n = 5653) who participated in the 2008–2012 Mental Health Surveillance Study. Mental disorders, including substance use disorders, were assessed by clinical interviewers using a semistructured diagnostic instrument. Analyses examined co-occurrence of mental disorders and associations with sociodemographic, functional impairment, and treatment correlates.Results
Approximately one-third of adults (31.1%, or more than 15 million) with a past-year mental disorder had a co-occurring mental disorder. Correlates of comorbidity in adjusted models included being of young age, being of non-Hispanic white race/ethnicity, having low family income, and living in a large metropolitan area. Adults with comorbid mental disorders had lower mean levels of functioning and were more likely to report past-year treatment than adults with a single disorder; they also had higher estimates of past-year perceived unmet need for care (21.7% vs. 11.6%, P < .01).Conclusions
About one in three adults with a mental disorder have a co-occurring mental disorder. Elucidating factors associated with co-occurrence may lend clues to shared etiologies, help improve prevention efforts, facilitate early identification, and improve treatment regimens. 相似文献7.
Wang Y Xu M Che M Von Hofe E Abbas A Kallinteris NL Lu X Liss ZJ Forman JD Hillman GG 《Human gene therapy》2005,16(2):187-199
Transfecting genes into tumors, to upregulate major histocompatibility complex (MHC) class I and class II molecules and inhibit MHC class II associated invariant chain (Ii), induces a potent anti-tumor immune response when preceded by tumor irradiation, in murine RM-9 prostate carcinoma. The transfected genes are cDNA plasmids for interferon-gamma (pIFN-gamma), MHC class II transactivator (pCIITA), an Ii reverse gene construct (pIi-RGC), and a subtherapeutic dose of adjuvant IL-2 (pIL-2). Responding mice rejected challenge with parental tumor and demonstrated tumor-specific cytotoxic T lymphocytes (CTLs). We have extended our investigation to determine the relative roles of each one of the four plasmids pIFN-gamma, pCIITA, pIi-RGC, and pIL-2 in conjunction with radiation for the induction of a curative immune response. Upregulation of MHC class I with pIFN-gamma or class II with pCIITA, separately, does not lead to a complete response even if supplemented with pIL-2 or pIi-RGC. An optimal and specific antitumor response is achieved in more than 50% of the mice when, after tumor irradiation, tumor cells are converted in situ to a MHC class I+/class II+/Ii- phenotype with pIFN-gamma, pCIITA, pIi-RGC, and pIL-2. We demonstrate further that both CD4+ helper T cells and CD8+ cytotoxic T cells are essential for induction of an antitumor response because in vivo depletion of either subset abrogates the response. The radiation contributes to the gene therapy by causing tumor debulking and increasing the permeability of tumors to infiltration of inflammatory cells. 相似文献
8.
Nina Beri Linda J. Patrick-Miller Brian L. Egleston Michael J. Hall Susan M. Domchek Mary B. Daly Pamela Ganschow Generosa Grana Olufunmilayo I. Olopade Dominique Fetzer Amanda Brandt Rachelle Chambers Dana F. Clark Andrea Forman Rikki Gaber Cassandra Gulden Janice Horte Jessica Long Terra Lucas Shreshtha Madaan Kristin Mattie Danielle McKenna Susan Montgomery Sarah Nielsen Jacquelyn Powers Kim Rainey Christina Rybak Michelle Savage Christina Seelaus Jessica Stoll Jill E. Stopfer Xinxin Yao Angela R. Bradbury 《Clinical genetics》2019,95(2):293-301
Telephone disclosure of cancer genetic test results is noninferior to in-person disclosure. However, how patients who prefer in-person communication of results differ from those who agree to telephone disclosure is unclear but important when considering delivery models for genetic medicine. Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone to in-person disclosure of genetic test results. We evaluated preferences for in-person disclosure, factors associated with this preference and outcomes compared to those who agreed to randomization. Among 1178 enrolled patients, 208 (18%) declined randomization, largely given a preference for in-person disclosure. These patients were more likely to be older (P = 0.007) and to have had multigene panel testing (P < 0.001). General anxiety (P = 0.007), state anxiety (P = 0.008), depression (P = 0.011), cancer-specific distress (P = 0.021) and uncertainty (P = 0.03) were higher after pretest counseling. After disclosure of results, they also had higher general anxiety (P = 0.003), depression (P = 0.002) and cancer-specific distress (P = 0.043). While telephone disclosure is a reasonable alternative to in-person disclosure in most patients, some patients have a strong preference for in-person communication. Patient age, distress and complexity of testing are important factors to consider and requests for in-person disclosure should be honored when possible. 相似文献
9.
Mohamed A. Kharfan-Dabaja Renju Raj Liana Nikolaenko Sairah Ahmed Nishitha Reddy Sunita Nathan Mohamad Cherry Najla El-Jurdi Cynthia Obiozor Timothy S. Fenske Joo Song Tariq Muzzafar Ernesto Ayala Bipin Savani Mohamad Khawandanah Paolo F. Caimi Mehdi Hamadani Stephen J. Forman Siddhartha Ganguly 《Biology of blood and marrow transplantation》2018,24(3):486-493
High-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) has been anecdotally prescribed in gray zone lymphoma (GZL), showing encouraging efficacy. We conducted a multicenter retrospective study aimed at assessing outcomes after auto-HCT in 32 patients with GZL treated at 9 transplantation centers in the United States. The median age of patients at transplantation was 38 years (range, 18 to 70 years), and the majority were male (n?=?21; 66%). The median number of lines of therapy before transplantation was 2 (range, 1 to 4). BEAM was the most commonly prescribed regimen (n?=?23; 72%). The median duration of follow-up for surviving patients was 34 months (range, 1 to 106 months). Median overall survival (OS) was not reached. The 3-year progression-free survival (PFS) and OS for all patients were 69% and 78%, respectively. Three-year PFS and OS were 100% for patients who received only 1 line of therapy before auto-HCT versus 65% (PFS, P?=?.25) and 75% (OS, P?=?.39) for those receiving >1 line. The cumulative incidence of relapse/progression was 4% at 1 year post-transplantation and 31% at 3 years post-transplantation. The 3-year nonrelapse mortality was 0%. These findings suggest that HDT and auto-HCT is an effective treatment in patients with GZL. Our findings ideally require confirmation in a larger cohort of patients, preferably in the setting of large prospective multicenter randomized controlled trials. However, we acknowledge that such studies could be difficult to conduct in patients with GZL owing to the disease's rarity. Alternatively, a multicenter prospective study that includes tissue banking and a data registry is warranted to help better understand the biology and natural history of the disease. 相似文献
10.
Efficacy of dicloxacillin-coated polyurethane catheters in preventing subcutaneous Staphylococcus aureus infection in mice. 总被引:2,自引:1,他引:2 下载免费PDF全文
In a mouse model, dicloxacillin-coated polyurethane catheters or control (uncoated) catheters were placed subcutaneously and then Staphylococcus aureus was inoculated at the time of insertion, 24 or 48 h later. The in vivo half-life of the antibiotic was 11 to 16 h. When 10(5) CFU of S. aureus were inoculated at the time of catheter insertion, dicloxacillin-coated catheters kept the number of S. aureus removed from catheters by sonication below 10(2) CFU at 12, 24, 48, and 96 h after inoculation compared with titers greater than 10(3.5) CFU for control catheters (P less than 0.05). When S. aureus was inoculated 24 h after catheter insertion, control catheters averaged greater than 10(2) CFU of S. aureus removed compared with less than 10(1.5) CFU for the dicloxacillin-coated catheters (P less than 0.05). No difference was found between coated and control catheters when S. aureus was inoculated 48 h after catheter insertion, but S. aureus titers averaged less than 10(2) CFU for all experimental groups. Our data suggest that in mice, regional prophylaxis of S. aureus subcutaneous space infection is feasible with catheters coated with dicloxacillin and that the presence of antibiotic is only necessary for the first 24 to 48 h. 相似文献